Visceral adipose tissue increases shortly after the cessation of GH therapy in adults with Prader-Willi syndrome.

  title={Visceral adipose tissue increases shortly after the cessation of GH therapy in adults with Prader-Willi syndrome.},
  author={Mikiko Koizumi and Shinobu Ida and Yasuko Shoji and Yukiko Nishimoto and Yuri Etani and Masanobu Kawai},
  journal={Endocrine journal},
  volume={65 11},
GH therapy in pediatric patients with Prader-Willi syndrome (PWS) improves body composition, but discontinuation of GH after achieving adult height has been implicated in its deterioration. Although there is evidence for the deleterious effects of visceral adipose tissue (VAT) rather than subcutaneous adipose tissue (SAT) on the development of obesity-related complications, the effects of GH discontinuation on fat distribution in adults with PWS has not been fully investigated. Therefore, we… 

Tables from this paper

Visceral adipose tissue resides within the reference range in children with Prader-Willi syndrome receiving nutritional intervention on a regular basis.
Investigation of fat distribution in genetically diagnosed Prader-Willi syndrome children found nutritional intervention is beneficial in maintaining VAT within the reference range during childhood, although excessive nutritional intervention may cause unfavorable effect on linear growth.
Growth Hormone Treatment for Adults With Prader-Willi Syndrome: A Meta-Analysis
GHt appears to be safe and improves body composition in adults with PWS, as poor body composition is closely linked to the observed high incidence of cardiovascular morbidity in adults in this vulnerable patient group.
Time for a general approval of growth hormone treatment in adults with Prader–Willi syndrome
Attention is drawn to the uneven global use of GH treatment, specifically in adults with PWS, and advocate for GH treatment to be approved internationally, not just for children, but also for adults withPWS and based only on the diagnosis of genetically confirmed PWS.
Early start of growth hormone is associated with positive effects on auxology and metabolism in Prader-Willi-syndrome
An early start of GHT during the first year of life seems to have a favorable effect on height-SDS and metabolic parameters.
Prader Willi syndrome: endocrine updates and new medical therapies.
Understanding the hormonal and metabolic drivers at work in PWS, as well as the nature of other hormonal dysfunction seen in the syndrome, is necessary to guide current management and future research directions.
Prader-Willi syndrome: an update on obesity and endocrine problems
The natural history of PWS and the mechanisms of hyperphagia and obesity, along with an update on obesity treatments and recommendations for screening and monitoring of various endocrine problems that can occur in PWS are discussed.
The use of growth hormone therapy in adults with Prader‐Willi syndrome: A systematic review
The aim of this study was to conduct a systematic review to evaluate the effects of GH on body composition, bone health and cardiovascular health in adults with PWS.
Somatrogon withdrawal
  • Medicine
    Reactions Weekly
  • 2019


Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader–Willi syndrome
To maintain good body composition and prevent complications of obesity, long‐term use of GH in adult PWS patients may be advisable.
Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study.
Salutary and sustained GH-induced changes in growth, body composition, BMD, and physical function in children with PWS can be achieved with daily administration of GH doses > or =1 mg/m(2).
Beneficial Effects of GH in Young Adults With Prader-Willi Syndrome: A 2-Year Crossover Trial.
GH-treated young adults with PWS who have attained AH benefit from continuation of GH treatment, and GH treatment maintains the improved body composition without safety concerns.
Characterization of fat distribution in Prader–Willi syndrome: Relationships with adipocytokines and influence of growth hormone treatment
To maintain lower VAT and prevent cardiovascular disease risk factors, GH treatment may be advisable even in adult patients with Prader–Willi syndrome.
Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects.
This 8-year study demonstrates that GH treatment is a potent force for counteracting the clinical course of obesity in children with Prader-Willi syndrome.
One year of growth hormone treatment in adults with Prader-Willi syndrome improves body composition: results from a randomized, placebo-controlled study.
Results showed that long-term treatment with GH effectively improved body composition and represents a safe, potential treatment option, relieving some of the negative consequences of PWS.
Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study
In conclusion GH treatment had beneficial effects on the abnormal body composition without serious adverse events making it a logic treatment option in adults with PWS.
Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy.
Adiponectin levels were increased, and inversely associated with triglyceride levels, in prepubertal, not overweight PWS children, although they had a relatively high body fat percentage.
Effects of growth hormone treatment in adults with Prader-Willi syndrome.
  • M. Butler, B. K. Smith, J. Donnelly
  • Medicine
    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • 2013
Early changes in body composition after cessation of growth hormone therapy in childhood-onset growth hormone deficiency.